A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs JVS 100 (Primary)
  • Indications Peripheral ischaemia
  • Focus Adverse reactions; First in man
  • Acronyms STOP-CLI
  • Sponsors Juventas Therapeutics
  • Most Recent Events

    • 18 Nov 2014 According to results presented at the 87th Annual Scientific Sessions of the American Heart Association, final 12 month data will be available in September 2014.
    • 18 Nov 2014 Interim 12 month efficacy results published in a Juventas Therapeutics media release.
    • 18 Nov 2014 Interim 12 month efficacy analysis results presented at the 87th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top